• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

EMA Tightens "Revolving Door" Rules for Members


May 6, 2015.

The European Medicines Agency (EMA) has updated its rules on declarations of interests for scientific committee members and experts.   The updates further strengthen EMA’s policy by restricting involvement of experts in the scientific assessment of medicines if they plan to take up a job in the pharmaceutical industry.    EMA considers that employment in a pharmaceutical company is incompatible with an involvement in Agency activities. Whenever a member of a scientific committee or working party informs the Agency that he/she intends to work for a pharmaceutical company, the Agency will immediately restrict the member from any participation in the evaluation of medicines. If necessary, the Agency will also verify whether the integrity of any ongoing or past scientific reviews in which that person was involved could have been compromised. These rules are reflected in the updated policy and in a new guidance document.     “The effective management of conflicts of interests is key to ensuring the independence and integrity of the Agency’s scientific recommendations,” commented Noël Wathion, EMA’s Chief Policy Adviser.   Source: http://www.ema.europa.eu/  

Related Videos